{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T16:32:17Z","timestamp":1790785937809,"version":"4.1.0"},"reference-count":34,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2005,4,1]],"date-time":"2005-04-01T00:00:00Z","timestamp":1112313600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2005,4,1]],"date-time":"2005-04-01T00:00:00Z","timestamp":1112313600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["ard.eular.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of the Rheumatic Diseases"],"published-print":{"date-parts":[[2005,4]]},"DOI":"10.1136\/ard.2004.025528","type":"journal-article","created":{"date-parts":[[2005,3,15]],"date-time":"2005-03-15T20:13:10Z","timestamp":1110917590000},"page":"620-625","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":302,"title":["Controlled clinical trial of IV cyclophosphamide versus IV methylprednisolone in severe neurological manifestations in systemic lupus erythematosus"],"prefix":"10.1016","volume":"64","author":[{"given":"L","family":"Barile-Fabris","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R","family":"Ariza-Andraca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L","family":"Olgu\u00edn-Ortega","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L J","family":"Jara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A","family":"Fraga-Mouret","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J M","family":"Miranda-Lim\u00f3n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J","family":"Fuentes de la Mata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P","family":"Clark","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F","family":"Vargas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J","family":"Alocer-Varela","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1136\/ard.2004.025528_bib1","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1093\/rheumatology\/41.6.605","article-title":"The central nervous system in systemic lupus erythematosus. Part I: Clinical syndromes: a literature investigation,","volume":"41","author":"Jennekens","year":"2002","journal-title":"Rheumatology (Oxford)"},{"key":"10.1136\/ard.2004.025528_bib2","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1191\/0961203303lu505oa","article-title":"Central nervous system lupus: a clinical approach to therapy","volume":"12","author":"Sanna","year":"2003","journal-title":"Lupus"},{"key":"10.1136\/ard.2004.025528_bib3","first-page":"295","article-title":"Pulse cyclophosphamide in the treatment of neuropsychiatric systemic lupus erythematosus","volume":"14","author":"Ramos","year":"1996","journal-title":"Clin Exp Rheumatol"},{"key":"10.1136\/ard.2004.025528_bib4","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1093\/qjmed\/81.3.975","article-title":"Pulse cyclophosphamide for severe neuropsychiatric lupus","volume":"81","author":"Boumpas","year":"1991","journal-title":"Q J Med"},{"key":"10.1136\/ard.2004.025528_bib5","first-page":"370","article-title":"Transverse myelitis in systemic lupus erythematosus\u2014the effect of IV pulse methylprednisolone and cyclophosphamide","volume":"19","author":"Barile","year":"1992","journal-title":"J Rheumatol"},{"key":"10.1136\/ard.2004.025528_bib6","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1007\/978-1-4684-5718-6_21","article-title":"Treatment combining plasmapheresis and pulse cyclophosphamide in severe systemic lupus erythematosus","volume":"260","author":"Schroeder","year":"1989","journal-title":"Adv Exp Med Biol"},{"key":"10.1136\/ard.2004.025528_bib7","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1056\/NEJMra993360","article-title":"Immunomodulation of autoimmune and inflammatory diseases with intravenous immune globulin","volume":"345","author":"Kazatchkine","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1136\/ard.2004.025528_bib8","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1007\/s100670050079","article-title":"Successful treatment of systemic lupus erythematosus cerebritis with intravenous immunoglobulin","volume":"18","author":"Sherer","year":"1999","journal-title":"Clin Rheumatol"},{"key":"10.1136\/ard.2004.025528_bib9","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1007\/BF00197524","article-title":"Central nervous system involvement in systemic lupus erythematosus: a new therapeutic approach with intrathecal dexamethasone and methotrexate","volume":"16","author":"Valesini","year":"1994","journal-title":"Springer Semin Immunopathol"},{"issue":"Suppl","key":"10.1136\/ard.2004.025528_bib10","first-page":"S31","article-title":"Central nervous system involvement due to systemic lupus erythematosus\/antiphospholipid syndrome: successful treatment with mycophenolate mofetil [abstract]","volume":"10","author":"Grisanti","year":"2001","journal-title":"Lupus"},{"key":"10.1136\/ard.2004.025528_bib11","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1191\/0961203303lu450xx","article-title":"Successful treatment with anti-CD20 monoclonal antibody (rituximab) of life-threatening refractory systemic lupus erythematosus with renal and central nervous system involvement","volume":"12","author":"Saito","year":"2003","journal-title":"Lupus"},{"key":"10.1136\/ard.2004.025528_bib12","first-page":"985","article-title":"Neuropsychiatric manifestations in systemic lupus erythematosus: prevalence and association with antiphospholipid antibodies","volume":"30","author":"Sanna","year":"2003","journal-title":"J Rheumatol"},{"key":"10.1136\/ard.2004.025528_bib13","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1191\/0961203303lu496oa","article-title":"APS and the brain","volume":"12","author":"Sastre","year":"2003","journal-title":"Lupus"},{"key":"10.1136\/ard.2004.025528_bib14","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1177\/096120339900800606","article-title":"The association between the antiphospholipid antibody syndrome and neuropsychological impairment in SLE","volume":"8","author":"Whitelaw","year":"1999","journal-title":"Lupus"},{"key":"10.1136\/ard.2004.025528_bib15","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1191\/096120399680411290","article-title":"A conceptual framework for clinical trials in SLE and other multisystem diseases","volume":"8","author":"Liang","year":"1999","journal-title":"Lupus"},{"key":"10.1136\/ard.2004.025528_bib16","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1002\/art.1780251101","article-title":"The 1982 revised criteria for the classification of systemic lupus erythematosus","volume":"25","author":"Tan","year":"1982","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard.2004.025528_bib17","first-page":"1319","article-title":"Antipospholipid\/cofactor syndromes","volume":"23","author":"Alarc\u00f3n-Segovia","year":"1996","journal-title":"J Rheumatol"},{"key":"10.1136\/ard.2004.025528_bib18","author":"HMSO","year":"1976","journal-title":"Medical Research Council aids to the diagnosis of peripheral nerve injuries"},{"key":"10.1136\/ard.2004.025528_bib19","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/S0002-9343(99)80078-3","article-title":"Role of intravenous cyclophosphamide in the treatment of severe neuropsychiatric systemic lupus erythematosus","volume":"98","author":"Neuwelt","year":"1995","journal-title":"Am J Med"},{"key":"10.1136\/ard.2004.025528_bib20","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1002\/sim.4780120517","article-title":"Interim analyses, stopping rules and data monitoring clinical trials in Europe","volume":"12","author":"Buyse","year":"1993","journal-title":"Stat Med"},{"key":"10.1136\/ard.2004.025528_bib21","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1056\/NEJM198806023182203","article-title":"Clinical and immunologic effects of monthly adminstration of intravenous cyclophosphamide in severe systemic lupus eryuthematosus","volume":"318","author":"McCune","year":"1988","journal-title":"N Engl J Med"},{"key":"10.1136\/ard.2004.025528_bib22","first-page":"225","article-title":"Hyperviscosity syndrome as the initial manifestation of systemic lupus erythematosus","volume":"16","author":"Jara","year":"1989","journal-title":"J Rheumatol"},{"key":"10.1136\/ard.2004.025528_bib23","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1016\/0002-9343(90)90509-C","article-title":"Electroconvulsive therapy and cyclophosphamide in combination for severe neuropsychiatric lupus with catatonia","volume":"88","author":"Fricchione","year":"1990","journal-title":"Am J Med"},{"issue":"Suppl","key":"10.1136\/ard.2004.025528_bib24","first-page":"S187","article-title":"The use of cyclophosphamide in the tratment of CNS lupus [abstract]","volume":"43","author":"Von","year":"1991","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard.2004.025528_bib25","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1177\/096120339600500409","article-title":"Transverse myelopathy in SLE: clinical features and functional outcomes","volume":"5","author":"Chan","year":"1996","journal-title":"Lupus"},{"key":"10.1136\/ard.2004.025528_bib26","first-page":"467","article-title":"Acute transverse myelopathy in systemic lupus erythematosus: clinical presentation, treatment and outcome","volume":"25","author":"Mok","year":"1998","journal-title":"J Rheumatol"},{"issue":"Suppl","key":"10.1136\/ard.2004.025528_bib27","first-page":"S57","article-title":"Long-term outcome of transverse myeltis in systemic lupus erythematosus and primary antiphospholipid syndrome [abstract]","volume":"40","author":"Barile","year":"1997","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard.2004.025528_bib28","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1002\/art.1780350606","article-title":"Committee on Prognosis studies in SLE. Derivation of the SLEDAI: a disease activity index for lupus patients,","volume":"35","author":"Bombardier","year":"1992","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard.2004.025528_bib29","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1002\/1529-0131(199904)42:4<599::AID-ANR2>3.0.CO;2-F","article-title":"Ad Hoc Committee on Neuropsychiatric Lupus Nomenclature. The American College of Rheumatology nomenclature and case definitions for neuropsychiatric lupus syndromes","volume":"42","author":"ACR","year":"1999","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard.2004.025528_bib30","first-page":"CD002265","article-title":"Cyclophosphamide vs. methylprednisolone for the treatment of neuropsychiatric involvement in systemic lupus erythematosus","author":"Trevisani","year":"2000","journal-title":"Cochrane Database Syst Rev"},{"issue":"Suppl","key":"10.1136\/ard.2004.025528_bib31","first-page":"S107","article-title":"Long term outcome of neuropsychiatric lupus [abstract]","volume":"7","author":"Barile","year":"1998","journal-title":"Lupus"},{"key":"10.1136\/ard.2004.025528_bib32","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1016\/0140-6736(92)92292-N","article-title":"evere lupus nephritis: Controlled trial of pulse methylprednisolone Vs two different regimens of pulse cyclophosphamide","volume":"340","author":"Boumpas","year":"1992","journal-title":"Lancet"},{"key":"10.1136\/ard.2004.025528_bib33","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1191\/0961203303lu503oa","article-title":"Endothelium and the brain in CNS lupus","volume":"12","author":"Meroni","year":"2003","journal-title":"Lupus"},{"key":"10.1136\/ard.2004.025528_bib34","doi-asserted-by":"crossref","first-page":"81","DOI":"10.2307\/2531632","article-title":"Study duration for clinical trials with survival response and early stopping rule","volume":"46","author":"Kim","year":"1990","journal-title":"Biometrics"}],"container-title":["Annals of the Rheumatic Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003496724430550?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003496724430550?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/ard.2004.025528","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,22]],"date-time":"2025-01-22T12:41:14Z","timestamp":1737549674000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0003496724430550"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,4]]},"references-count":34,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2005,4]]}},"alternative-id":["S0003496724430550"],"URL":"https:\/\/doi.org\/10.1136\/ard.2004.025528","relation":{},"ISSN":["0003-4967"],"issn-type":[{"value":"0003-4967","type":"print"}],"subject":[],"published":{"date-parts":[[2005,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Controlled clinical trial of IV cyclophosphamide versus IV methylprednisolone in severe neurological manifestations in systemic lupus erythematosus","name":"articletitle","label":"Article Title"},{"value":"Annals of the Rheumatic Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1136\/ard.2004.025528","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2005 Copyright 2005 by Annals of the Rheumatic Diseases, Published by Elsevier Inc. Published by Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}